Absci Corporation (ABSI)

Market Cap	391.75M
Revenue (ttm)	4.14M
Net Income (ttm)	-113.30M
Shares Out	149.52M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,627,629
Open	2.570
Previous Close	2.550
Day's Range	2.530 - 2.660
52-Week Range	2.010 - 6.330
Beta	2.02
Analysts	Strong Buy
Price Target	7.98 (+204.58%)
Earnings Date	Nov 11, 2025

About ABSI

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 22, 2021
• Employees: 157
• Stock Exchange: NASDAQ
• Ticker Symbol: ABSI
• Website: https://www.absci.com

Financial Performance

In 2024, Absci's revenue was $4.53 million, a decrease of -20.71% compared to the previous year's $5.72 million. Losses were -$103.11 million, -6.75% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price target is $7.98, which is an increase of 204.58% from the latest price.

Price Target

$7.98

(204.58% upside)

Analyst Consensus: Strong Buy